SAN FRANCISCO--(BUSINESS WIRE)--Celtaxsys Inc., a privately-held biopharmaceutical company developing a new class of drugs to treat chronic inflammatory disorders through innate immunity, today announced that Mr. Khalil Barrage has been appointed to the Board of Directors.
“As a as a major healthcare investor, Khalil brings a depth of experience and expertise to our leadership team. We are pleased that he has chosen to join Celtaxsys as the Company moves its lead compound, CTX-4430, through clinical development,” said Dr. Michael R. Hanley, CEO and Chairman.
Mr. Barrage added, “Celtaxsys is an exciting company with the potential to improve the lives of patients with cystic fibrosis and other devastating inflammatory lung diseases. Celtaxsys is poised to enable a significant leap forward in options for these patients."
A Managing Director in Invus Fund’s New York office, Khalil joins the board as an experienced investor with a broad experience in the biotech and healthcare sectors.
About CTX-4430
CTX-4430 is a clinical-stage drug candidate designed to treat chronic inflammatory disorders including cystic fibrosis and other serious pulmonary inflammatory diseases such as systemic sclerosis and idiopathic pulmonary fibrosis. CTX-4430 works by inhibiting Leukotriene A4 hydrolase (LTA4H), the major rate-limiting step in Leukotriene B4 (LTB4) production. LTB4 stands out as an early chemoattractant mediator of many types of pulmonary and systemic inflammation. Orally administered, CTX-4430 has been shown to reduce LTB4 production and to improve clinical signs and symptoms of the inflammatory disease state. CTX-4430 has the potential to become a novel treatment that combines successfully with new and current therapies in pulmonary and other inflammatory disorders.
About Celtaxsys, Inc.
Celtaxsys is a privately-held clinical stage drug discovery and development company focused on developing new treatments for inflammatory diseases by modulating innate immunity. The Company is building a sustainable pipeline of first-in-class drugs with novel mechanisms of action. For more information, please visit www.celtaxsys.com.
